OPTIMAL TREATMENT STRATEGY FOR PATIENTS WITH PROGRESSIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

The treatment of common forms of squamous cell carcinoma of the organs located on the head and neck that are not subject to surgical treatment is limited to the use of chemoradiotherapy with platinum derivatives or drug therapy with platinum-containing regimens. With the progression of the disease, ineffective 2‑line cytostatics were prescribed that did not fundamentally change the course of the tumor process. The introduction into clinical practice of drugs of the original mechanism of action has significantly increased the effectiveness of drug therapy during progression after platinum-containing chemotherapy. The article presents two clinical observations that demonstrate the relevance of the strategy of using inhibitors of immune response control points after platinum preparations.

1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359 (11):1116–27. DOI: 10.1056/NEJMoa0802656

2. Bolotina LV, Vladimirova LYu, Dengina NV, Novik AV, Romanov IS. Practical recommendations for the treatment of malignant tumors of the head and neck. Malignant Tumoursis. 2017;7 (3 S2):66–76. DOI: 10.18027/2224–5057–20l7–7-3s2–66–76 (In Russian).

3. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a southwest oncology group study. Cancer Treat Rep. 1985 Jun;69 (6):577–81.

4. Williams SD, Velez-Garcia E, Essessee I, Ratkin G, Birch R, Einhorn LH. Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer. 1986 Jan 1;57 (1):18–23. DOI: 10.1002/1097–0142 (19860101)57:13.0.co;2-v,

5. Forastiere A, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. A Southwest Oncology Group Study. J Clin Oncol. 1992 Aug;10 (8):1245–51. DOI: 10.1200/JCO.1992.10.8.1245

6. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or aſter platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16 (5):583–94. DOI: 10.1016/S1470–2045 (15)70124–5.

7. Franceschi S, Munoz N, BoschXF, Snijders PJ, WalboomersJM. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev. 1996 Jul;5 (7):567–75.

8. Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012 Apr;22 (2):128–42. DOI: 10.1016/j.semradonc.2011.12.004.

9. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol. 2002 Dec;12 (6):431–41.

10. Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, et al: Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016 May;56:1–7. DOI: 10.1016/j.oraloncology.2016.02.011

11. Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, et al. Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity. Cancer. 2016 Dec 1;122 (23):3624–3631. DOI: 10.1002/cncr.30227

12. Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011 Nov 2;306 (17):1891–901. DOI: 10.1001/jama.2011.1592.

13. Deeb R, Sharma S, Mahan M, Al-Khudari S, Hall F, Yoshida A, Schweitzer V. Head and neck cancer in transplant recipients. Laryngoscope. 2012 Jul;122 (7):1566–9. DOI: 10.1002/lary.23328

14. Kruse ALD, Gratz KW. Oral carcinoma aſter hematopoietic stem cell transplantation — a new classification based on a literature review over 30 years. Head Neck Oncol. 2009 Jul 22;1:29. DOI: 10.1186/1758–3284–1-29.

15. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G. Distribution of immune cells in head and neck cancer: CD8+ T cells and CD20+ B cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer. 2009 Aug 22;9:292. DOI: 10.1186/1471–2407–9-292

16. Cho Y-A, Yoon H-J, Lee J-I, Hong S-P, Hong S-D. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011 Dec;47 (12):1148–53. DOI: 10.1016/j.oraloncology.2011.08.007

17. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013 Jan 1;73 (1):128–38. DOI: 10.1158/0008– 5472.CAN-12–2606.

18. Ukpo OC, Thorstad WL, Lewis JS. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2013 Jun;7 (2):113–21. DOI: 10.1007/s12105–012–0406-z.

19. ASCO 2017: Abstracts Head and Neck Pai et al. #6040

20. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366 (26):2443–54. DOI: 10.1056/NEJMoa1200690.

21. Seiwert T, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. J Clin Oncol. 2014;32 (5S) (suppl; abstr 6011).

22. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti- PD-L1 antibody. J Clin Oncol. 2014;32 (5s) (suppl; abstr 3002).

23. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375 (19):1856– 1867. DOI: 10.1056/NEJMoa1602252

24. Robert L, Ferris et al. Presented at ASTRO, Feb 2017, abstract LBA10.

25. Cohen EE, et al. ESMO 2017 (Abstract LBA45).

26. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head and Neck Cancers. Version 2.2018.

27. Ribas A, et al. Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? Clin Cancer Res. 2009 Dec 1;15 (23):7116–8. DOI: 10.1158/1078–0432.CCR-09–2376.

28. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15 (23):7412–20. DOI: 10.1158/1078–0432.CCR-09–1624

29. Lynch T, et al. Overall survival and progression free survival results for a randomized phase 2 trial of Ipilimumab and Paclitaxel/Carboplatin in first-line stage IIIB/IV NSCLC. Presented at: ESMO, 2010; poster 375PD.

30. Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019; 37 (suppl; abstr 6000).